It has been suggested that “hot” tumors may respond effectively to immune checkpoint inhibitors (ICIs) if they possess growth-promoting lymphocytes, genomic susceptibility, and a prior antitumor immune response, as indicated by complementary determinations such as the expression of anti-PD-L1 on cancer-associated immune cells [23]. This evidence concerns the gene CD274 and cancer.